000 | 01998 a2200577 4500 | ||
---|---|---|---|
005 | 20250516205850.0 | ||
264 | 0 | _c20170313 | |
008 | 201703s 0 0 eng d | ||
022 | _a1098-6596 | ||
024 | 7 |
_a10.1128/AAC.02579-13 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aSims, Karen D | |
245 | 0 | 0 |
_aRandomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection. _h[electronic resource] |
260 |
_bAntimicrobial agents and chemotherapy _cJun 2014 |
||
300 |
_a3496-503 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 |
_aAntiviral Agents _xadministration & dosage |
650 | 0 | 4 |
_aBenzazepines _xadministration & dosage |
650 | 0 | 4 | _aCohort Studies |
650 | 0 | 4 | _aDouble-Blind Method |
650 | 0 | 4 | _aDrug Resistance, Viral |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aGenotype |
650 | 0 | 4 | _aHalf-Life |
650 | 0 | 4 |
_aHepacivirus _xclassification |
650 | 0 | 4 |
_aHepatitis C _xdrug therapy |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aIndoles _xadministration & dosage |
650 | 0 | 4 | _aInterferons |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aPhenotype |
650 | 0 | 4 |
_aRNA, Viral _xblood |
650 | 0 | 4 |
_aRNA-Dependent RNA Polymerase _xantagonists & inhibitors |
650 | 0 | 4 |
_aViral Nonstructural Proteins _xantagonists & inhibitors |
650 | 0 | 4 | _aYoung Adult |
700 | 1 | _aLemm, Julie | |
700 | 1 | _aEley, Timothy | |
700 | 1 | _aLiu, Menping | |
700 | 1 | _aBerglind, Anna | |
700 | 1 | _aSherman, Diane | |
700 | 1 | _aLawitz, Eric | |
700 | 1 | _aVutikullird, Apinya B | |
700 | 1 | _aTebas, Pablo | |
700 | 1 | _aGao, Min | |
700 | 1 | _aPasquinelli, Claudio | |
700 | 1 | _aGrasela, Dennis M | |
773 | 0 |
_tAntimicrobial agents and chemotherapy _gvol. 58 _gno. 6 _gp. 3496-503 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1128/AAC.02579-13 _zAvailable from publisher's website |
999 |
_c23738078 _d23738078 |